Anxiolytics and Antidepressants Contribute to Symptomatic Improvement in Patients with Primary Hemifacial Spasm Coupled with Anxiety and Depression
10.12007/j.issn.0258-4646.2017.03.016
- VernacularTitle:抗焦虑抑郁药物改善伴焦虑抑郁的原发性面肌痉挛症状有效性的研究
- Author:
Haoran ZHU
;
Ning ZHANG
;
Xinxin LI
;
Yuling LU
- Keywords:
hemifacial spasm;
botulinum toxin A;
anxiety;
depression
- From:
Journal of China Medical University
2017;46(3):255-257
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the symptom improvement of anxiolytics and antidepressant to hemifacial spasm(HFS)patients with anxiety and depression. Methods A total of 60 HFS patients with anxiety and depression were enrolled for the study and divided into experimental group and control group. Experimental group were treated with escitalopram and BTX-A ,and control group only received BTX-A. SAS and SDS were used to test all the patients before and after treatment. Results Both experimental group and control group were significantly improved after BTX-A therapy. There was no different between two groups at 1 week and 1 month,respectively. At 2 weeks and 3 months,more obvious improvement was seen in experimental group. The SAS and the SDS standard average scores of experimental group were significantly decreased compared with the control group. There was statistical significance in control group after 1 month and 3 months treatment(P<0.05),and in experimental group,the differences appeared after 2-week treatment(P<0.05). Additionally,after 1 month treatment,there were statistical differences between the two groups(P<0.05),and experimental group shown a longer effective period compared with control group. Conclusion Anxiety and depression state serves as a complication of HFS ,which is positively correlated with HFS. HFS patients with anxiety and depression benefit better from escital-opram and BTX-A combination therapy than BTX-A alone.
